The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

Basit Öğe Kaydı
dc.authoridFayda, Merdan/0000-0002-2800-5327
dc.authoridCicin, Irfan/0000-0002-7584-3868;
dc.authorwosidFayda, Merdan/AAF-7370-2019
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidFayda, Merdan/F-5092-2012
dc.authorwosidKocak, Zafer/AEG-7828-2022
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.contributor.authorUygun, Kazim
dc.contributor.authorAksu, Gorkem
dc.contributor.authorCicin, Irfan
dc.contributor.authorKaragol, Hakan
dc.contributor.authorKocak, Zafer
dc.contributor.authorFayda, Merdan
dc.contributor.authorBinici, Ahmet
dc.date.accessioned2024-06-12T11:09:27Z
dc.date.available2024-06-12T11:09:27Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground To evaluate the efficiency of docetaxel as second line chemotherapy in patients with platinum-refractory non-small cell lung carcinoma (NSCLC). Patients and methods Fifty-two patients with locally advanced or metastatic NSCLC who had platinum-refractory disease (progressed through or within 3 months of completion of first line therapy) and an Eastern Cooperative Oncology Group performance (ECOG) status 0-2 were treated with second-line chemotherapy consisting of single agent docetaxel (100 mg/m2, intravenously, on day 1 of a 21-day cycle). The median number of treatment cycles was 4 (2-6). Disease-free (DFS) and overall survival (OS), response rates and toxicity were evaluated. Results The median progression-free survival of patients was 3 months (95% CI: 0.01-5.99) and overall survival was 7.2 months (95% CI: 2.2-9.5). One-year overall survival rate was 29%. Disease control (complete response, partial response, or stable disease) was achieved in 25 patients (48%) and overall response rate was 13% (7 patients). There were no complete responses. Seventeen patients (33%) had stable disease and twenty-seven patients (52%) had progressive disease. Age, gender, stage at diagnosis (IIIB vs. IV), performance status at initiation of second-line therapy (0-1 vs. 2) histopathological type (epidermoid vs. others), grade, LDH, albumin, weight loss were evaluated as prognostic factors; however, none of these had a significant affect on survivals. The protocol was well tolerated and there were no toxic deaths. Grade III-IV anemia was present in 8 patients (15%) and thrombopenia in 12 (23%) patients. The most frequent grade 3-4 toxicities were leucopenia (52%) and neutropenia (48%). Febril neutropenia occurred in 14 patients (26%). No patients experienced grade III-IV mucositis and diarrhea. Totally, the need of a dose reduction was about 25% and treatment delay (4-9 days) occurred in 5 patients (10%) and 7 patients (13%), respectively, because of toxicity. Conclusions Second-line chemotherapy with single-agent docetaxel offers a small but significant survival advantage with acceptable toxicity for patients with advanced NSCLC who have platinum-refractory disease.en_US
dc.identifier.doi10.1007/s12032-008-9055-1
dc.identifier.endpage414en_US
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue4en_US
dc.identifier.pmid18320363en_US
dc.identifier.scopus2-s2.0-58549108446en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage408en_US
dc.identifier.urihttps://doi.org/10.1007/s12032-008-9055-1
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22797
dc.identifier.volume25en_US
dc.identifier.wosWOS:000261288000008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNSCLCen_US
dc.subjectDocetaxelen_US
dc.subjectSecond-Lineen_US
dc.subjectChemotherapyen_US
dc.subjectGemcitabineen_US
dc.subjectRadiotherapyen_US
dc.subjectPhase-Ii Trialen_US
dc.subjectEvery 3 Weeksen_US
dc.subject2nd-Line Treatmenten_US
dc.subjectSupportive Careen_US
dc.subjectContaining Chemotherapyen_US
dc.subjectRandomized-Trialen_US
dc.subjectCancer Nsclcen_US
dc.subjectGemcitabineen_US
dc.subjectCombinationen_US
dc.subjectGefitiniben_US
dc.titleThe efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu